

HemoShear Therapeutics Engages with European Metabolic Disease Consortium

HemoShear's Co-founder and Head of Innovation, Brian Wamhoff, PhD, gave an invited talk this week at the Annual Meeting of the European Registry and Network for Intoxication Type Metabolic Disorders (E-IMD) in Brussels.

During his talk, titled "HemoShear's Drug Discovery Programs for IEMs", Dr. Wamhoff explained how HemoShear has developed a robust drug discovery program for inborn errors of metabolism (IEMs). The company has made significant progress by utilizing its REVEAL-Tx™ platform to recreate the human pathophysiology of several rare diseases in the laboratory to understand the complex disease processes, identify and validate promising treatment approaches, and study the effects of drug candidates.

HemoShear is now in the late preclinical stage of developing therapies for propionic acidemia (PA) and methylmalonic acidemia (MMA). These rare metabolic diseases are caused by the deficiency of certain enzymes required to metabolize proteins, leading to the rapid buildup of life-threatening toxins in the body. PA & MMA result in a range of debilitating symptoms and developmental delays, brain damage and premature death. While some symptoms can be controlled somewhat by dietary restrictions, there are currently no effective treatments that significantly improve the quality of life or lifespan for children with these diseases.

"As our PA and MMA drug development program advances, it is important for us to engage with this consortium of European experts," said Dr. Wamhoff. "We are seeking to learn more about these rare diseases for design of our clinical studies and to identify clinicians that want to participate in our studies in Europe."

The E-IMD was co-funded by the European Union to establish a patient-based [registry](#) that includes comprehensive data on more than 1,100 patients with metabolic disorders. They have published evidence-based clinical care guidelines, original research articles and established a [website](#) for dissemination of information to patients, families and healthcare professionals.



HemoShear Therapeutics discovers novel biological targets and advances drug programs to treat metabolic disorders with significant unmet patient need.

Contact us: [Email](#) [Twitter](#) [LinkedIn](#)

[Unsubscribe](#)